Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost- effectiveness

Página do item simplificado
dc.contributor.authorNsengiyumva, Ntwali Placide
dc.contributor.authorCampbell, Jonathon R.
dc.contributor.authorOxlade, Olivia
dc.contributor.authorVesga, Juan F.
dc.contributor.authorLienhardt, Christian
dc.contributor.authorTrajman, Anete
dc.contributor.authorFalzon, Dennis
dc.contributor.authorBoon, Saskia Den
dc.contributor.authorArinaminpathy, Nimalan
dc.contributor.authorSchwartzman, Kevin
dc.date.accessioned2024-12-13T20:04:54Z
dc.date.available2024-12-13T20:04:54Z
dc.date.issued2022
dc.description.abstractBackground Shorter, safer, and cheaper tuberculosis (TB) preventive treatment (TPT) regimens will enhance uptake and effectiveness. WHO developed target product profiles describing mini- mum requirements and optimal targets for key attributes of novel TPT regimens. We per- formed a cost-effectiveness analysis addressing the scale-up of regimens meeting these criteria in Brazil, a setting with relatively low transmission and low HIV and rifampicin-resis- tant TB (RR-TB) prevalence, and South Africa, a setting with higher transmission and higher HIV and RR-TB prevalence. Methods and findings We used outputs from a model simulating scale-up of TPT regimens meeting minimal and optimal criteria. We assumed that drug costs for minimal and optimal regimens were identi- cal to 6 months of daily isoniazid (6H). The minimal regimen lasted 3 months, with 70% com- pletion and 80% efficacy; the optimal regimen lasted 1 month, with 90% completion and 100% efficacy. Target groups were people living with HIV (PLHIV) on antiretroviral treatment and household contacts (HHCs) of identified TB patientsAU. The: Icha statusngedquoidenwas tifiedin 6HdexT at 2019 BpatientstoidentifiedTBpatients:Ifthisisnotcorrect; pleaseeditasnecessary: coverage levels for PLHIV and HHCs. We projected TB cases and deaths, TB-associated disability-adjusted life years (DALYs), and costs (in 2020 US dollars) associated with TB from a TB services perspective from 2020 to 2035, with 3% annual discounting. We esti- mated the expected costs and outcomes of scaling up 6H, the minimal TPT regimen, or the optimal TPT regimen to reach all eligible PLHIV and HHCs by 2023, compared to the status quo. Maintaining current 6H coverage in Brazil (0% of HHCs and 30% of PLHIV treated) would be associated with 1.1 (95% uncertainty range [UR] 1.1–1.2) million TB cases, 123,000 (115,000–132,000) deaths, and 2.5 (2.1–3.1) million DALYs and would cost $1.1 ($1.0–$1.3) billion during 2020–2035. Expanding the 6H, minimal, or optimal regimen to 100% coverage among eligible groups would reduce DALYs by 0.5% (95% UR 1.2% reduc- tion, 0.4% increase), 2.5% (1.8%–3.0%), and 9.0% (6.5%–11.0%), respectively, with addi- tional costs of $107 ($95–$117) million and $51 ($41–$60) million and savings of $36 ($14– $58) million, respectively. Compared to the status quo, costs per DALY averted were $7,608 and $808 for scaling up the 6H and minimal regimens, respectively, while the optimal regimen was dominant (cost savings, reduced DALYs). In South Africa, maintaining current 6H coverage (0% of HHCs and 69% of PLHIV treated) would be associated with 3.6 (95% UR 3.0–4.3) million TB cases, 843,000 (598,000–1,201,000) deaths, and 36.7 (19.5–58.0) million DALYs and would cost $2.5 ($1.8–$3.6) billion. Expanding coverage with the 6H, minimal, or optimal regimen would reduce DALYs by 6.9% (95% UR 4.3%–95%), 15.5% (11.8%–18.9%), and 38.0% (32.7%–43.0%), respectively, with additional costs of $79 (−$7, $151) million and $40 (−$52, $140) millionAUand: savings Ichangedofadd$608 itionalc ($443–$832) ostsof 79ðsamillion, vings7;respec- additional151Þmillionand40ðsavings52; additional140Þmilliontoadditionalcostsof 79ð 7; 151Þmillionand40ð 52;140Þmillion:Ifthiseditdoesnotcaptureyourmeaning; pleaseeditasnecessary: tively. Compared to the status quo, estimated costs per DALY averted were $31 and $7 for scaling up the 6H and minimal regimens, while the optimal regimen was dominant. Study limitations included the focus on 2 countries, and no explicit consideration of costs incurred before the decision to prescribe TPT. Conclusions Our findings suggest that scale-up of TPT regimens meeting minimum or optimal require- ments would likely have important impacts on TB-associated outcomes and would likely be cost-effective or cost saving.
dc.identifier.citationNsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, Trajman A, Falzon D, Den Boon S, Arinaminpathy N, Schwartzman K. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Med. 2022 Jun 13;19(6):e1004032. doi: 10.1371/journal.pmed.1004032.
dc.identifier.otherDOI: 10.1371/journal.pmed.1004032
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/720
dc.language.isoen
dc.publisherPLOS Medicine
dc.subjectAntitubercular Agents / therapeutic useen
dc.subjectBrazil / epidemiologyen
dc.subjectCost-Benefit Analysisen
dc.subjectHIV Infections* / drug therapyen
dc.subjectHIV Infections* / epidemiologyen
dc.subjectHIV Infections* / prevention & controlen
dc.subjectHumansen
dc.subjectSouth Africa / epidemiologyen
dc.subjectTuberculosis, Multidrug-Resistant* / drug therapyen
dc.titleScaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost- effectiveness
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Nsengiyumva NP et al_PLOS Med.pdf
Tamanho:
257.28 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente